Headache News

A novel digital therapeutic for migraine prevention met its primary endpoint of reducing the number of monthly migraine days, according to results from a phase 3 clinical trial.

In patients with difficult-to-treat migraine, IV infusion of a novel monoclonal antibody provided superior migraine frequency relief compared with placebo in as early as 4 weeks, data show.

Prodromal treatment with 100 mg ubrogepant was associated with greater functionality, fewer activity limitations and a high degree of satisfaction at 24 hours in patients with migraine, according to research published in Neurology.

According to results of a six-nation global survey, individuals with migraine experienced a high level of symptom burden and severity, negatively affecting their quality of life including mood.

Eyenavision and Avulux have launched Chemistrie Avulux, an eyeglass clip-on option for people with migraines and light sensitivity.

Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and adolescents, according to topline results from the phase 3 SPACE study.

A clinical-stage neuroscience-focused biopharmaceutical company has received new international patents related to an investigational neuroactive pherine nasal spray to potentially treat individuals with migraine.

No significant differences were found in clinical outcomes or recovery time in college athletes who returned to play following concussion compared with those immediately removed, according to research from Neurosurgical Focus.

SAN DIEGO — Contraceptive use did not significantly increase risk of vascular events overall for women who experience migraines, although those who experience migraine with aura had an increased risk, data show.